Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nextcure Inc (NQ: NXTC )

1.370 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.370
Bid (Size) 1.300 (100)
Ask (Size) 1.830 (5)
Prev. Close 1.370
Today's Range 1.370 - 1.370
52wk Range 0.9800 - 2.570
Shares Outstanding 27,903,027
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024
From NextCure
Via GlobeNewswire
NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024
Poster presentation highlights strong safety and pharmacokinetic profiles for LNCB74 
From NextCure
Via GlobeNewswire

Performance

YTD
+19.13%
+19.13%
1 Month
-40.69%
-40.69%
3 Month
+12.30%
+12.30%
6 Month
+28.04%
+28.04%
1 Year
-9.87%
-9.87%

More News

Read More
NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board
From NextCure
Via GlobeNewswire
NXTC Stock Earnings: NextCure Beats EPS for Q4 2023
Via InvestorPlace
NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference
From NextCure
Via GlobeNewswire
Wall Street’s Favorite Penny Stocks? 7 Names That Could Make You Filthy Rich
Via InvestorPlace
Topics Economy
Exposures Interest Rates
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
NextCure Provides Business Update and Reports Full Year 2023 Financial Results
From NextCure
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances
From NextCure
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders
From NextCure
Via GlobeNewswire
NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury
From NextCure
Via GlobeNewswire
Why Amtech Systems Shares Are Trading Higher By Over 30%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
US Stocks Higher; Initial Jobless Claims Fall To 202,000
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
NextCure Provides Year-End Clinical Pipeline Updates
From NextCure
Via GlobeNewswire
NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference
From NextCure
Via GlobeNewswire
NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML
From NextCure
Via GlobeNewswire
NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results
From NextCure
Via GlobeNewswire
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)
From NextCure
Via GlobeNewswire
NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer’s Disease
From NextCure
Via GlobeNewswire
A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC
From NextCure
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.